The two firms will offer their technologies and services to patients in Hong Kong, Japan, and Macau to improve drug dosing and prescriptions.
The company shared validation data this week that it said led the FDA to approve use of the test in a new prospective trial of Roche's Tecentriq in NSCLC.
The company said that it plans to use the funds to develop NGS assays in the oncology and precision medicine space, and expand its US commercial team.
PacBio is refining the CRISPR/Cas9 capture technique with several early- access sites and plans to launch it more broadly in 2018.
A pair of studies has established a potential role for specific gut bacteria in the progression of MS, suggesting therapeutic targeting of the microbiota as a potential treatment.
The deals will expand the availability of Admera's pharmacogenomics testing services to markets including Singapore, Hong Kong, Korea, and Taiwan.
Next year, the company will submit regulatory filings for the drug in two molecularly defined indications and a next-generation sequencing companion diagnostic.
The firms will use MGI's sequencing technology and Curetis' sample prep platform and antibiotic resistance database to develop IVDs, initially for China.
Last week, the company launched whole-genome sequencing of children for customers of its ViaCord cord blood and tissue banking business.
The firms will comarket AATI's automated CE systems for quality control analysis of nucleic acids in Illumina's next-generation sequencing workflows.
The nanopore ZMW can enable lower starting amounts of DNA for PacBio sequencing, and may eventually enable direct RNA sequencing.
A team of Australian researchers reconstructed 7,280 bacterial and 623 archaeal genomes from publicly availably metagenomic data.
The company's Hong Kong laboratory was established in 2010 and was accredited by the College of American Pathologists in 2013.
Researchers have argued that the facial prediction claims are overblown and serve Human Longevity's financial interests in proprietary genomic databases.
A new genome sequence study suggests sequence conservation is more common in HPV16 isolates from individuals with cancer or pre-cancerous conditions.
The two projects aim to use genomics to prevent the spread of drug-resistant bacteria and expand the use of genomic testing in cancer, respectively.
Illumina has filed a new lawsuit against Premaitha, claiming it infringes on an Illumina patent related to noninvasive prenatal testing.
Patients are organizing themselves in groups based on the molecular features driving their tumors to better advocate for themselves, raise money, and influence research.
With the cash, WuXi NextCode will build out its AI and deep learning, seek partnerships in precision medicine and diagnostics, and commercialize genomic tests.
Johns Hopkins researchers added protein analysis to circulating tumor DNA testing to better detect early-stage pancreatic cancer.
Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.
The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.
In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.
China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.